CLINICAL TRIALS PROFILE FOR BUNAVAIL
✉ Email this page to a colleague
All Clinical Trials for BUNAVAIL
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02516436 ↗ | The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects | Withdrawn | BioDelivery Sciences International | Phase 3 | 1969-12-31 | A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. Study duration is up to five days and includes a maximum of 3 days confinement in the clinic. Opioid dependent subjects who provide informed consent meet all entry criteria are eligible for enrollment into the study. |
NCT03993392 ↗ | SUBLOCADE Rapid Initiation Study | Completed | Indivior Inc. | Phase 4 | 2019-08-29 | This study is to evaluate the safety and tolerability of initiating SUBLOCADEā¢ treatment following a shorter period of transmucosal (TM) buprenorphine treatment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BUNAVAIL
Condition Name
Clinical Trial Locations for BUNAVAIL
Trials by Country
Clinical Trial Progress for BUNAVAIL
Clinical Trial Phase
Clinical Trial Sponsors for BUNAVAIL
Sponsor Name